LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Is it bradycardia or something else causing symptoms?

    Olshansky, Brian / Feigofsky, Suzy / Cannom, David S

    HeartRhythm case reports

    2018  Volume 4, Issue 12, Page(s) 601–603

    Language English
    Publishing date 2018-10-06
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834871-0
    ISSN 2214-0271
    ISSN 2214-0271
    DOI 10.1016/j.hrcr.2018.09.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment.

    Olshansky, Brian / Cannom, David / Fedorowski, Artur / Stewart, Julian / Gibbons, Christopher / Sutton, Richard / Shen, Win-Kuang / Muldowney, James / Chung, Tae Hwan / Feigofsky, Suzy / Nayak, Hemal / Calkins, Hugh / Benditt, David G

    Progress in cardiovascular diseases

    2020  Volume 63, Issue 3, Page(s) 263–270

    Abstract: Although diagnostic criteria have been developed characterizing postural orthostatic tachycardia syndrome (POTS), no single set of criteria is universally accepted. Furthermore, there are gaps in the present criteria used to identify individuals who have ...

    Abstract Although diagnostic criteria have been developed characterizing postural orthostatic tachycardia syndrome (POTS), no single set of criteria is universally accepted. Furthermore, there are gaps in the present criteria used to identify individuals who have this condition. The reproducibility of the physiological findings, the relationship of symptoms to physiological findings, the presence of symptoms alone without any physiological findings and the response to various interventions confuse rather than clarify this condition. As many disease entities can be confused with POTS, it becomes critical to identify what this syndrome is. What appears to be POTS may be an underlying condition that requires specific therapy. POTS is not simply orthostatic intolerance and symptoms or intermittent orthostatic tachycardia but the syndrome needs to be characterized over time and with reproducibility. Here we address critical issues regarding the pathophysiology and diagnosis of POTS in an attempt to arrive at a rational approach to categorize the syndrome with the hope that it may help both better identify individuals and better understand approaches to therapy.
    MeSH term(s) Blood Pressure ; Diagnosis, Differential ; Heart Rate ; Humans ; Postural Orthostatic Tachycardia Syndrome/diagnosis ; Postural Orthostatic Tachycardia Syndrome/epidemiology ; Postural Orthostatic Tachycardia Syndrome/physiopathology ; Postural Orthostatic Tachycardia Syndrome/therapy ; Posture ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results
    Language English
    Publishing date 2020-03-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 209312-1
    ISSN 1873-1740 ; 1532-8643 ; 0033-0620
    ISSN (online) 1873-1740 ; 1532-8643
    ISSN 0033-0620
    DOI 10.1016/j.pcad.2020.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.

    Gopinathannair, Rakesh / Merchant, Faisal M / Lakkireddy, Dhanunjaya R / Etheridge, Susan P / Feigofsky, Suzy / Han, Janet K / Kabra, Rajesh / Natale, Andrea / Poe, Stacy / Saha, Sandeep A / Russo, Andrea M

    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing

    2020  Volume 59, Issue 2, Page(s) 329–336

    Abstract: Background: Cardiovascular and arrhythmic events have been reported in hospitalized COVID-19 patients. However, arrhythmia manifestations and treatment strategies used in these patients have not been well-described. We sought to better understand the ... ...

    Abstract Background: Cardiovascular and arrhythmic events have been reported in hospitalized COVID-19 patients. However, arrhythmia manifestations and treatment strategies used in these patients have not been well-described. We sought to better understand the cardiac arrhythmic manifestations and treatment strategies in hospitalized COVID-19 patients through a worldwide cross-sectional survey.
    Methods: The Heart Rhythm Society (HRS) sent an online survey (via SurveyMonkey) to electrophysiology (EP) professionals (physicians, scientists, and allied professionals) across the globe. The survey was active from March 27 to April 13, 2020.
    Results: A total of 1197 respondents completed the survey with 50% of respondents from outside the USA, representing 76 countries and 6 continents. Of respondents, 905 (76%) reported having COVID-19-positive patients in their hospital. Atrial fibrillation was the most commonly reported tachyarrhythmia whereas severe sinus bradycardia and complete heart block were the most common bradyarrhythmias. Ventricular tachycardia/ventricular fibrillation arrest and pulseless electrical activity were reported by 4.8% and 5.6% of respondents, respectively. There were 140 of 631 (22.2%) respondents who reported using anticoagulation therapy in all COVID-19-positive patients who did not otherwise have an indication. One hundred fifty-five of 498 (31%) reported regular use of hydroxychloroquine/chloroquine (HCQ) + azithromycin (AZM); concomitant use of AZM was more common in the USA. Sixty of 489 respondents (12.3%) reported having to discontinue therapy with HCQ + AZM due to significant QTc prolongation and 20 (4.1%) reported cases of Torsade de Pointes in patients on HCQ/chloroquine and AZM. Amiodarone was the most common antiarrhythmic drug used for ventricular arrhythmia management.
    Conclusions: In this global survey of > 1100 EP professionals regarding hospitalized COVID-19 patients, a variety of arrhythmic manifestations were observed, ranging from benign to potentially life-threatening. Observed adverse events related to use of HCQ + AZM included prolonged QTc requiring drug discontinuation as well as Torsade de Pointes. Large prospective studies to better define arrhythmic manifestations as well as the safety of treatment strategies in COVID-19 patients are warranted.
    MeSH term(s) Anti-Arrhythmia Agents/administration & dosage ; Arrhythmias, Cardiac/diagnostic imaging ; Arrhythmias, Cardiac/drug therapy ; Arrhythmias, Cardiac/epidemiology ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Cross-Sectional Studies ; Electrocardiography/methods ; Female ; Humans ; Incidence ; Long QT Syndrome/diagnostic imaging ; Long QT Syndrome/drug therapy ; Long QT Syndrome/epidemiology ; Male ; Pandemics/prevention & control ; Pandemics/statistics & numerical data ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Prognosis ; Severity of Illness Index ; Surveys and Questionnaires ; Survival Rate ; Torsades de Pointes/diagnostic imaging ; Torsades de Pointes/drug therapy ; Torsades de Pointes/epidemiology ; Treatment Outcome
    Chemical Substances Anti-Arrhythmia Agents
    Keywords covid19
    Language English
    Publishing date 2020-06-03
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1329179-8
    ISSN 1572-8595 ; 1383-875X
    ISSN (online) 1572-8595
    ISSN 1383-875X
    DOI 10.1007/s10840-020-00789-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

    Gopinathannair, Rakesh / Merchant, Faisal M / Lakkireddy, Dhanunjaya R / Etheridge, Susan P / Feigofsky, Suzy / Han, Janet K / Kabra, Rajesh / Natale, Andrea / Poe, Stacy / Saha, Sandeep A / Russo, Andrea M

    J Interv Card Electrophysiol

    Abstract: BACKGROUND: Cardiovascular and arrhythmic events have been reported in hospitalized COVID-19 patients. However, arrhythmia manifestations and treatment strategies used in these patients have not been well-described. We sought to better understand the ... ...

    Abstract BACKGROUND: Cardiovascular and arrhythmic events have been reported in hospitalized COVID-19 patients. However, arrhythmia manifestations and treatment strategies used in these patients have not been well-described. We sought to better understand the cardiac arrhythmic manifestations and treatment strategies in hospitalized COVID-19 patients through a worldwide cross-sectional survey. METHODS: The Heart Rhythm Society (HRS) sent an online survey (via SurveyMonkey) to electrophysiology (EP) professionals (physicians, scientists, and allied professionals) across the globe. The survey was active from March 27 to April 13, 2020. RESULTS: A total of 1197 respondents completed the survey with 50% of respondents from outside the USA, representing 76 countries and 6 continents. Of respondents, 905 (76%) reported having COVID-19-positive patients in their hospital. Atrial fibrillation was the most commonly reported tachyarrhythmia whereas severe sinus bradycardia and complete heart block were the most common bradyarrhythmias. Ventricular tachycardia/ventricular fibrillation arrest and pulseless electrical activity were reported by 4.8% and 5.6% of respondents, respectively. There were 140 of 631 (22.2%) respondents who reported using anticoagulation therapy in all COVID-19-positive patients who did not otherwise have an indication. One hundred fifty-five of 498 (31%) reported regular use of hydroxychloroquine/chloroquine (HCQ) + azithromycin (AZM); concomitant use of AZM was more common in the USA. Sixty of 489 respondents (12.3%) reported having to discontinue therapy with HCQ + AZM due to significant QTc prolongation and 20 (4.1%) reported cases of Torsade de Pointes in patients on HCQ/chloroquine and AZM. Amiodarone was the most common antiarrhythmic drug used for ventricular arrhythmia management. CONCLUSIONS: In this global survey of > 1100 EP professionals regarding hospitalized COVID-19 patients, a variety of arrhythmic manifestations were observed, ranging from benign to potentially life-threatening. Observed adverse events related to use of HCQ + AZM included prolonged QTc requiring drug discontinuation as well as Torsade de Pointes. Large prospective studies to better define arrhythmic manifestations as well as the safety of treatment strategies in COVID-19 patients are warranted.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #505746
    Database COVID19

    Kategorien

  5. Article ; Online: COVID-19 and cardiac arrhythmias

    Gopinathannair, Rakesh / Merchant, Faisal M. / Lakkireddy, Dhanunjaya R. / Etheridge, Susan P. / Feigofsky, Suzy / Han, Janet K. / Kabra, Rajesh / Natale, Andrea / Poe, Stacy / Saha, Sandeep A. / Russo, Andrea M.

    Journal of Interventional Cardiac Electrophysiology ; ISSN 1383-875X 1572-8595

    a global perspective on arrhythmia characteristics and management strategies

    2020  

    Keywords Physiology (medical) ; Cardiology and Cardiovascular Medicine ; covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    DOI 10.1007/s10840-020-00789-9
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top